Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

December 31, 2008

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.

Trial Locations (3)

63110

St Louis

91010

Duarte

90095-1678

Los Angeles

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00358644 - Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter